424 related articles for article (PubMed ID: 1364090)
1. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
[TBL] [Abstract][Full Text] [Related]
3. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.
Reubi JC; Kvols LK; Waser B; Nagorney DM; Heitz PU; Charboneau JW; Reading CC; Moertel C
Cancer Res; 1990 Sep; 50(18):5969-77. PubMed ID: 2168286
[TBL] [Abstract][Full Text] [Related]
4. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors.
Kölby L; Wängberg B; Ahlman H; Tisell LE; Fjälling M; Forssell-Aronsson E; Nilsson O
World J Surg; 1998 Jul; 22(7):679-83. PubMed ID: 9606281
[TBL] [Abstract][Full Text] [Related]
6. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E; Deshpande HA; Stein SM
Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
[TBL] [Abstract][Full Text] [Related]
7. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
8. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor imaging: predictive and prognostic considerations.
Anthony LB; Martin W; Delbeke D; Sandler M
Digestion; 1996; 57 Suppl 1():50-3. PubMed ID: 8813470
[TBL] [Abstract][Full Text] [Related]
10. Factor analysis of dynamic series (FADS) in somatostatin receptor imaging.
Kolesnikov-Gauthier H; Huglo D; Nocaudie M; Marchandise X
J Nucl Med; 1999 Jan; 40(1):33-9. PubMed ID: 9935053
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin analogue phase I trials in neuroendocrine neoplasms.
Anthony L; Johnson D; Hande K; Shaff M; Winn S; Krozely M; Oates J
Acta Oncol; 1993; 32(2):217-23. PubMed ID: 7686764
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptors: clinical implications for endocrinology and oncology.
Lamberts SW; de Herder WW; van Koetsveld PM; Koper JW; van der Lely AJ; Visser-Wisselaar HA; Hofland LJ
Ciba Found Symp; 1995; 190():222-36; discussion 236-9. PubMed ID: 7587649
[TBL] [Abstract][Full Text] [Related]
13. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of Octreotide: Clinical Implications for Anesthesiologists and Associated Risks.
Borna RM; Jahr JS; Kmiecik S; Mancuso KF; Kaye AD
Anesthesiol Clin; 2017 Jun; 35(2):327-339. PubMed ID: 28526153
[TBL] [Abstract][Full Text] [Related]
15. Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors.
Wynick D; Bloom SR
J Clin Endocrinol Metab; 1991 Jul; 73(1):1-3. PubMed ID: 1646213
[TBL] [Abstract][Full Text] [Related]
16. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma.
Vainas I; Koussis Ch; Pazaitou-Panayiotou K; Drimonitis A; Chrisoulidou A; Iakovou I; Boudina M; Kaprara A; Maladaki A
J Exp Clin Cancer Res; 2004 Dec; 23(4):549-59. PubMed ID: 15743023
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors.
Kvols LK; Brown ML; O'Connor MK; Hung JC; Hayostek RJ; Reubi JC; Lamberts SW
Radiology; 1993 Apr; 187(1):129-33. PubMed ID: 8383865
[TBL] [Abstract][Full Text] [Related]
19. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview.
Warner RR; O'dorisio TM
Semin Nucl Med; 2002 Apr; 32(2):79-83. PubMed ID: 11965602
[TBL] [Abstract][Full Text] [Related]
20. Use of somatostatin analog in management of carcinoid syndrome.
Vinik A; Moattari AR
Dig Dis Sci; 1989 Mar; 34(3 Suppl):14S-27S. PubMed ID: 2920654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
